目的 观察清肺消炎丸联合莫西沙星治疗社区获得性肺炎的临床疗效和安全性.方法 选取2013年3月—2014年4月天津市第二医院收治的社区获得性肺炎患者90例,随机分为对照组(45例)和治疗组(45例).对照组静脉滴注盐酸莫西沙星氯化钠注射液,0.4 g/次,1次/d;治疗期间若病情好转,抗生素可改为盐酸莫西沙星片0.4 g/次,1次/d.治疗组在对照组治疗的基础上,口服清肺消炎丸60粒/次,3次/d.两组均连续治疗10 d.治疗后,评价两组的临床疗效,同时比较患者临床症状、体征以及实验室疗效指标的变化.结果 治疗组和对照组愈显率分别为93.33%、80.00%,两组愈显率比较差异有统计学意义(P<0.05).治疗组患者退热、咳嗽咳痰缓解、肺部啰音消失情况优于对照组,两组比较差异有统计学意义(P<0.05).两组患者治疗第3、10天白细胞计数、中性粒细胞比例及C反应蛋白(CRP)均较治疗前显著下降,同组治疗前后差异有统计学意义(P<0.05);治疗组在治疗第3、10天CRP低于对照组,两组比较差异有统计学意义(P<0.05).结论 清肺消炎丸联合莫西沙星治疗社区获得性肺炎具有较好的临床疗效,可改善患者症状和实验室检查,且无不良反应,值得临床推广应用.

Objective To observe the clinical efficacy and safety of Qingfei Xiaoyan Pills combined with moxifloxacin in treatment of community acquired pneumonia. Methods Patients (90 cases) with community acquired pneumonia who came to the Second Hospital of Tianjin from March 2013 to April 2014 were randomly divided into control (45 cases) and treatment (45 cases) groups. The patients in the control group were iv administered with Moxifloxacin Hydrochloride and Sodium Chloride Injection (0.4 g/time), once daily. If the patients got better during the treatment, antibiotics could be changed to Moxifloxacin Hydrochloride Tablets, 0.4 g/time, once daily. The patients in the treatment group were po administered with Qingfei Xiaoyan Pills on the basis of control group, 60 grains/time, three times daily. The patients in two groups were treated for 10 d. After treatment, the treatment efficacy was evaluated, while the changes of clinical symptoms, signs, and laboratory indexes were compared. Results The markedly effective rate in the treatment and control groups were 93.33% and 80.00%, respectively, and there were differences between the two groups (P < 0.05). Defervescence, ease of cough and expectoration, and situation of lung sound disappeared in treatment group were better than those in the control group, with the significant difference between two groups (P < 0.05). The count of white blood cells, neutrophils ratio, and CRP decreased significantly in two groups on days 3 and 10 of treatment, and the difference was statistically significant in the same group (P < 0.05). CRP in the treatment group was lower than that in the control group on days 3 and 10 of treatment, with the significant difference between two groups (P < 0.05). Conclusion Qingfei Xiaoyan Pills combined with moxifloxacin has good clinical effect in treatment of community acquired pneumonia, and can improve symptoms and laboratory examination with no adverse reactions, which is worthy of clinical application.